SkinBioTherapeutics Income Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2020 - 2016
Operating Revenue	4.64	1.21	0.13	0.07	-	Upgrade
Revenue	4.64	1.21	0.13	0.07	-	Upgrade
Revenue Growth (YoY)	283.74%	815.26%	76.64%	-	-	Upgrade
Cost of Revenue	1.78	0.53	0.05	0.03	-	Upgrade
Gross Profit	2.86	0.68	0.09	0.05	-	Upgrade
Selling, General & Admin	3.86	3.03	2.15	2.17	0.99	Upgrade
Research & Development	0.13	0.56	0.93	0.86	0.51	Upgrade
Operating Expenses	3.98	3.59	3.08	3.03	1.5	Upgrade
Operating Income	-1.12	-2.91	-3	-2.98	-1.5	Upgrade
Interest Expense	-0.09	-0.04	-0.01	-0.01	-0	Upgrade
Other Non Operating Income (Expenses)	0.5	-	-	-	-	Upgrade
Pretax Income	-0.72	-2.95	-3.01	-2.99	-1.5	Upgrade
Income Tax Expense	-0.02	-0.07	-0.17	-0.2	-0.07	Upgrade
Net Income	-0.7	-2.88	-2.84	-2.79	-1.43	Upgrade
Net Income to Common	-0.7	-2.88	-2.84	-2.79	-1.43	Upgrade
Shares Outstanding (Basic)	225	186	165	157	147	Upgrade
Shares Outstanding (Diluted)	225	186	165	157	147	Upgrade
Shares Change (YoY)	20.57%	13.10%	5.06%	6.87%	14.53%	Upgrade
EPS (Basic)	-0.00	-0.02	-0.02	-0.02	-0.01	Upgrade
EPS (Diluted)	-0.00	-0.02	-0.02	-0.02	-0.01	Upgrade
Free Cash Flow	-1.24	-2.74	-2.73	-2.67	-1.56	Upgrade
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.02	-0.01	Upgrade
Gross Margin	61.65%	56.51%	64.51%	60.64%	-	Upgrade
Operating Margin	-24.21%	-240.36%	-2271.26%	-3988.83%	-	Upgrade
Profit Margin	-15.01%	-237.95%	-2146.91%	-3735.37%	-	Upgrade
Free Cash Flow Margin	-26.76%	-226.80%	-2071.02%	-3575.44%	-	Upgrade
EBITDA	-0.82	-2.77	-2.99	-2.98	-1.5	Upgrade
EBITDA Margin	-17.65%	-229.38%	-	-	-	Upgrade
D&A For EBITDA	0.3	0.13	0.01	0	0	Upgrade
EBIT	-1.12	-2.91	-3	-2.98	-1.5	Upgrade
EBIT Margin	-24.21%	-240.36%	-	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.